SA
AMGN icon

Strategic Advocates’s Amgen AMGN Stock Holding History

Strategic Advocates’s Portfolio AMGN Stock Details AMGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.05K Buy
25
+1
+4% +$342 0.04% 168
2026
Q1 		$8.44K Buy
24
+3
+14% +$1.07K 0.04% 162
2025
Q4 		$6.9K Hold
21
– – ﹤0.01% 402
2025
Q3 		$5.93K Buy
+21
New +$6.09K ﹤0.01% 396

Other funds holding AMGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Strategic Advocates's AMGN Position: Q2 2026 in Review

Strategic Advocates increased its Amgen (AMGN) stake by 4.2% in Q2 2026, buying an estimated $342 and bringing the position to 25 shares worth $9.05K. The position accounts for 0.04% of the portfolio, ranked #168.

Strategic Advocates first reported a position in AMGN in Q3 2025 and has held it in 4 quarters since. 3,151 funds tracked by Wall St. Rank hold AMGN as of Q2 2026.

  • Strategic Advocates held 25 shares of Amgen worth $9.05K as of Q2 2026.
  • Strategic Advocates bought 1 Amgen share in Q2 2026, an estimated $342.
  • Amgen made up 0.04% of Strategic Advocates's portfolio in Q2 2026, its #168 holding.
  • Strategic Advocates first reported a position in Amgen in Q3 2025 and has held it in 4 quarters since.
  • 3,151 funds tracked by Wall St. Rank held Amgen as of Q2 2026.

Based on Strategic Advocates's 13F filing for Q2 2026, filed 13 Aug 2026.